Inflammatory Arthritis in Patients With Myelodysplastic Syndromes A Multicenter Retrospective Study and Literature Review of 68 Cases

被引:39
作者
Mekinian, Arsene [1 ]
Braun, Thorsten [2 ]
Decaux, Olivier [3 ]
Falgarone, Geraldine [4 ]
Toussirot, Eric [5 ,6 ]
Raffray, Loic [7 ]
Omouri, Mohamed [8 ]
Gombert, Bruno [9 ]
De Wazieres, Benoit [10 ]
Buchdaul, Anne-Laure [11 ]
Ziza, Jean-Marc [12 ]
Launay, David [13 ]
Denis, Guillaume [14 ]
Madaule, Serge [15 ]
Rose, Christian [16 ]
Grignano, Eric [1 ]
Fenaux, Pierre [2 ]
Fain, Olivier [1 ]
机构
[1] Univ Paris 13, Hop Jean Verdier, AP HP, Serv Med Interne, F-93140 Bondy, France
[2] Univ Paris 13, AP HP, Serv Hematol Clin, Bobigny, France
[3] Univ Rennes 1, Hop Univ Rennes, Serv Med Interne, Rennes, France
[4] Univ Paris 13, Univ Sorbonne Paris Cite, Hop Avicenne, Serv Rhumatol,Li2P,EA4222, Bobigny, France
[5] CHU Besancon, Ctr Invest Clin Biotherapie CBT 506, Besancon, France
[6] CHU Besancon, Serv Rhumatol, Besancon, France
[7] CHU Bordeaux, Serv Med Interne, Bordeaux, France
[8] CH Romilly Seine, Serv Rhumatol, Romilly Sur Seine, France
[9] Hop La Rochelle, Serv Med Interne, La Rochelle, France
[10] CHU Nimes, Serv Med Interne & Geriatr, Nimes, France
[11] CH Douai, Serv Med Interne, Douai, France
[12] CH Croix St Simon, Serv Rhumatol, Paris, France
[13] Univ Lille 2, CHU Lille, Serv Med Interne, Lille, France
[14] Hop Rochefort, Serv Med Interne, Rochefort, France
[15] CHG Albi, Serv Med Interne, Albi, France
[16] Univ Nord France, Hop St Vincent de Paul, UC Lille, Serv Hematol Clin, Lille, France
关键词
SERONEGATIVE SYMMETRICAL SYNOVITIS; POLYMYALGIA-RHEUMATICA; PITTING EDEMA; IMMUNOLOGICAL ABNORMALITIES; AUTOIMMUNE MANIFESTATIONS; REFRACTORY-ANEMIA; CLASSIFICATION; POLYARTHRITIS; ASSOCIATION; LEUKEMIA;
D O I
10.1097/MD.0000000000000011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We describe the characteristics and outcome of inflammatory arthritis in patients with myelodysplastic syndrome (MDS) in a French multicenter retrospective study. Twenty-two patients with MDS (median age, 77.5 yr [interquartile range, 69-81]; 10 women) were included. Inflammatory arthritis presented as polyarthritis in 17 cases (77%) and with symmetric involvement in 15 cases (68%). At diagnosis, the median disease activity score 28 based on C-reactive protein (DAS28-CRP) was 4.5 [2-6.5]. Two patients had anti-citrullinated protein antibodies (ACPAs), and 1 had radiologic erosions. The median time between the diagnoses of arthritis and MDS was 10 months [6-42], with a median articular symptom duration of 3 months [2-8]. The diagnosis of both diseases was concomitant in 6 cases (27%); arthritis preceded MDS in 12 cases (55%), and occurred after MDS in 4 (18%). While the number of swollen and tender joints significantly decreased during follow-up, as did the median DAS28-CRP (from 4.3 [3.8-4.6] at baseline to 2.9 [1.75-3.3]; p < 0.05), CRP remained elevated (CRP >20 mg/ L) in 8 patients (42%). Nevertheless, radiographic progression and new ACPA positivity were not observed during a median follow-up of 29 months [9-76]. While most of the patients were treated with steroids (n = 16) for arthritis, additional treatment was administered in only 4 patients (hydroxychloroquine, n = 2; sulfasalazine [Salazopyrin] and etanercept, n = 1, respectively). Eleven patients died during follow-up from acute myeloid leukemia (n = 5); infections (n = 3); or cerebral bleeding, cardiorespiratory failure, or undetermined cause (n = 1, respectively). Inflammatory arthritis associated with MDS can have various presentations and is often seronegative and nonerosive. Steroids alone are the most common treatment in MDS-associated arthritis, but that treatment is insufficient to control arthritis. Steroid-sparing strategies need to be identified.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 47 条
[1]   Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy [J].
Aggarwal, Shikhar ;
van de Loosdrecht, Arjan A. ;
Alhan, Canan ;
Ossenkoppele, Gert J. ;
Westers, Theresia M. ;
Bontkes, Hetty J. .
BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (05) :568-581
[2]   Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells [J].
Al Ustwani, Omar ;
Wallace, Paul K. ;
Ambrus, Julian, Jr. ;
Wetzler, Meir .
LEUKEMIA RESEARCH, 2011, 35 (05) :E35-E36
[3]   2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative [J].
Aletaha, Daniel ;
Neogi, Tuhina ;
Silman, Alan J. ;
Funovits, Julia ;
Felson, David T. ;
Bingham, Clifton O., III ;
Birnbaum, Neal S. ;
Burmester, Gerd R. ;
Bykerk, Vivian P. ;
Cohen, Marc D. ;
Combe, Bernard ;
Costenbader, Karen H. ;
Dougados, Maxime ;
Emery, Paul ;
Ferraccioli, Gianfranco ;
Hazes, Johanna M. W. ;
Hobbs, Kathryn ;
Huizinga, Tom W. J. ;
Kavanaugh, Arthur ;
Kay, Jonathan ;
Kvien, Tore K. ;
Laing, Timothy ;
Mease, Philip ;
Menard, Henri A. ;
Moreland, Larry W. ;
Naden, Raymond L. ;
Pincus, Theodore ;
Smolen, Josef S. ;
Stanislawska-Biernat, Ewa ;
Symmons, Deborah ;
Tak, Paul P. ;
Upchurch, Katherine S. ;
Vencovsky, Jiri ;
Wolfe, Frederick ;
Hawker, Gillian .
ARTHRITIS AND RHEUMATISM, 2010, 62 (09) :2569-2581
[4]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[5]   Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group [J].
Baron, Frederic ;
Suciu, Stefan ;
Amadori, Sergio ;
Muus, Petra ;
Zwierzina, Heinz ;
Denzlinger, Claudio ;
Delforge, Michel ;
Thyss, Antoine ;
Selleslag, Dominik ;
Indrak, Karel ;
Ossenkoppele, Gert ;
de Witte, Theo .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (04) :529-533
[6]  
Berthelot JM, 1997, REV RHUM, V64, P95
[7]   Myelodysplastic syndromes and systemic manifestations. A non-casual association. [J].
Berthier, S ;
Magy, N ;
Gil, H ;
Schneider, MB ;
Vuitton, DA ;
Dupond, JL .
REVUE DE MEDECINE INTERNE, 2001, 22 (05) :428-432
[8]  
Beyne-Rauzy O, 2001, ANN MED INTERNE, V152, P276
[9]  
BILLSTROM R, 1995, EUR J HAEMATOL, V55, P42
[10]   Immunological abnormalities in myelodysplastic syndromes. Prospective study (series of 40 patients) [J].
Bouali, F ;
Berrah, A ;
Ahmed-Bouali, DS ;
Harrieche, F ;
Benhalima, M ;
Hamladji, RM ;
Arrada, M .
REVUE DE MEDECINE INTERNE, 2005, 26 (10) :777-783